Perspectives

Updates in newly diagnosed and R/R AML

Expert discussion on MDS data at ASH 2021

Key takeaways in MPNs

Future directions in AML: targeted therapies, antibody-radiation conjugates & new combinations

Teclistamab’s place in the myeloma treatment landscape

Myeloma highlights: UK perspective

Key MDS updates from the 2021 ASH meeting

The relevance of SCT in multiple myeloma

Advice for MDS patients in the COVID-19 era

Assessing MRD in hematologic malignancies

Discussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies

AML data at ASH 2021 and implications on clinical practice

Response-adapted treatment in CLL

Standardization MRD monitoring in clinical trials

The future of CLL treatment

Myelofibrosis treatment in 5 years